Agios director Paul Clancy to retire; Jeff Capello elected to board, to chair Audit Committee
AGIOS PHARMACEUTICALS, INC.
Paul Clancy will not stand for re-election at 2023 Annual Meeting; ceases as Audit Committee chair and Compensation & People Committee member.
Jeff Capello elected as class II director effective at 2023 Annual Meeting; appointed Audit Committee chair.
Capello receives $50,000/yr director cash retainer plus $20,000/yr for Audit Chair role; initial equity grant of stock options ($472,500 Black-Scholes) and RSUs ($157,500).
Capello enters into standard indemnification agreement with the company.
On April 17, 2023, Paul Clancy notified Agios Pharmaceuticals, Inc. (the “Company”) of his decision not to stand for re-election to the Board of Directors (the “Board”) of the Company when his current term expires at the Company’s 2023 Annual Meeting of Stockholders.
On April 18, 2023, the Board of the Company, upon the recommendation of the Nominating and Corporate Governance Committee of the Board (the “Corporate Governance Committee”), elected Jeff Capello as a director, effective as of the date of the Corporation’s 2023 Annual Meeting of Stockholders (the “Effective Date”).
Key facts
Extracted from this filing and checked against the source text.
Executive changeSEC 8-K Item 5.02confidence 0.95
Paul Clancy resigned as Director at AGIOS PHARMACEUTICALS, INC..
Action
resigned
Role
Director
Exact text from the filing
On April 17, 2023, Paul Clancy notified Agios Pharmaceuticals, Inc. (the “Company”) of his decision not to stand for re-election to the Board of Directors (the “Board”) of the Company when his current term expires at the Company’s 2023 Annual Meeting of Stockholders.
Jeff Capello was elected as Director at AGIOS PHARMACEUTICALS, INC..
Action
elected
Role
Director
Exact text from the filing
On April 18, 2023, the Board of the Company, upon the recommendation of the Nominating and Corporate Governance Committee of the Board (the “Corporate Governance Committee”), elected Jeff Capello as a director, effective as of the date of the Corporation’s 2023 Annual Meeting of Stockholders (the “Effective Date”).
This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice.
See methodology for how this pipeline works.